186 related articles for article (PubMed ID: 32384031)
1. New Orodispersible Mini Tablets of Enalapril Maleate by Direct Compression for Pediatric Patients.
Ortega CA; Favier LS; Cianchino VA; Cifuente DA
Curr Drug Deliv; 2020; 17(6):505-510. PubMed ID: 32384031
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of two novel co-processed excipients for direct compression of orodispersible tablets and mini-tablets.
Kokott M; Lura A; Breitkreutz J; Wiedey R
Eur J Pharm Biopharm; 2021 Nov; 168():122-130. PubMed ID: 34474110
[TBL] [Abstract][Full Text] [Related]
3. New orodispersible mini-tablets for paediatric use - A comparison of isomalt with a mannitol based co-processed excipient.
Lura A; Luhn O; Suarez Gonzales J; Breitkreutz J
Int J Pharm; 2019 Dec; 572():118804. PubMed ID: 31678381
[TBL] [Abstract][Full Text] [Related]
4. Enalapril maleate orally disintegrating tablets: tableting and in vivo evaluation in hypertensive rats.
Tawfeek HM; Faisal W; Soliman GM
Pharm Dev Technol; 2018 Jun; 23(5):496-503. PubMed ID: 28489472
[TBL] [Abstract][Full Text] [Related]
5. A Novel Development of Levothyroxine Sodium Orodispersible Mini Tablets for the Treatment of Pediatrics Hypothyroidism.
Henestrosa C; Olivera C; Flor S; Lucangioli S; Vacatello A; Ortega CA; Favier LS; Cifuente DA
Recent Adv Drug Deliv Formul; 2023 Sep; ():. PubMed ID: 37723959
[TBL] [Abstract][Full Text] [Related]
6. Orally disintegrating mini-tablets (ODMTs)--a novel solid oral dosage form for paediatric use.
Stoltenberg I; Breitkreutz J
Eur J Pharm Biopharm; 2011 Aug; 78(3):462-9. PubMed ID: 21324357
[TBL] [Abstract][Full Text] [Related]
7. Design and evaluation of a new formulation of enalapril maleate tablet.
Bibi R; Naqvi BS; Shoaib MH; Rahim N
Pak J Pharm Sci; 2011 Apr; 24(2):211-5. PubMed ID: 21454172
[TBL] [Abstract][Full Text] [Related]
8. Flexible and precise dosing of enalapril maleate for all paediatric age groups utilizing orodispersible minitablets.
Thabet Y; Walsh J; Breitkreutz J
Int J Pharm; 2018 Apr; 541(1-2):136-142. PubMed ID: 29474896
[TBL] [Abstract][Full Text] [Related]
9. Transfer and scale-up of the manufacturing of orodispersible mini-tablets from a compaction simulator to an industrial rotary tablet press.
Lura A; Elezaj V; Kokott M; Fischer B; Breitkreutz J
Int J Pharm; 2021 Jun; 602():120636. PubMed ID: 33895296
[TBL] [Abstract][Full Text] [Related]
10. Study of the effect of formulation variables on the characteristics of combination tablets containing enalapril maleate and indapamide as active substances using experimental design.
Szabó ZI; Székely-Szentmiklósi B; Deák B; Székely-Szentmiklósi I; Kovács B; Zöldi K; Sipos E
Acta Pharm; 2016 Jun; 66(2):191-206. PubMed ID: 27279063
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence of enalapril oral solution for treatment of pediatric hypertension and enalapril tablets.
Moffett BS; DiSanto AR; Espinosa O; Hou J; Colabuono P
Clin Pharmacol Drug Dev; 2014 Nov; 3(6):493-8. PubMed ID: 27129124
[TBL] [Abstract][Full Text] [Related]
12. A pharmaceutical study on chlorzoxazone orodispersible tablets: formulation, in-vitro and in-vivo evaluation.
Moqbel HA; ElMeshad AN; El-Nabarawi MA
Drug Deliv; 2016 Oct; 23(8):2998-3007. PubMed ID: 26828616
[TBL] [Abstract][Full Text] [Related]
13. Investigating the Impact of Co-processed Excipients on the Formulation of Bromhexine Hydrochloride Orally Disintegrating Tablets (ODTs).
Woyna-Orlewicz K; Brniak W; Tatara W; Strzebońska M; Haznar-Garbacz D; Szafraniec-Szczęsny J; Antosik-Rogóż A; Wojteczko K; Strózik M; Kurek M; Jachowicz R; Mendyk A
Pharm Res; 2023 Dec; 40(12):2947-2962. PubMed ID: 37726407
[TBL] [Abstract][Full Text] [Related]
14. Continuous manufacturing and analytical characterization of fixed-dose, multilayer orodispersible films.
Thabet Y; Lunter D; Breitkreutz J
Eur J Pharm Sci; 2018 May; 117():236-244. PubMed ID: 29499348
[TBL] [Abstract][Full Text] [Related]
15. Orodispersible Carbamazepine/Hydroxypropyl-β-Cyclodextrin Tablets Obtained by Direct Compression with Five-in-One Co-processed Excipients.
Conceição J; Adeoye O; Cabral-Marques H; Concheiro A; Alvarez-Lorenzo C; Sousa Lobo JM
AAPS PharmSciTech; 2020 Jan; 21(2):39. PubMed ID: 31897724
[TBL] [Abstract][Full Text] [Related]
16. Impact of lubrication on key properties of orodispersible minitablets in comparison to conventionally sized orodispersible tablets.
Kuck J; Breitkreutz J
Eur J Pharm Biopharm; 2022 Nov; 180():71-80. PubMed ID: 36067955
[TBL] [Abstract][Full Text] [Related]
17. Physicochemical stability of captopril and enalapril extemporaneous formulations for pediatric patients.
Casas M; Álvarez J; Lucero MJ
Pharm Dev Technol; 2015 May; 20(3):271-8. PubMed ID: 24279906
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Disintegrant-addition Methods on the Compounding of Orodispersible Tablets.
Mahesparan VA; Bin Abd Razak FS; Ming LC; Uddin AH; Sarker MZI; Bin LK
Int J Pharm Compd; 2020; 24(2):148-155. PubMed ID: 32196477
[TBL] [Abstract][Full Text] [Related]
19. Development and Optimization of Sildenafil Orodispersible Mini-Tablets (ODMTs) for Treatment of Pediatric Pulmonary Hypertension Using Response Surface Methodology.
Alalaiwe A; Alsenaidy MA; Almalki ZS; Fayed MH
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986784
[TBL] [Abstract][Full Text] [Related]
20. Model-dependent pharmacokinetic analysis of enalapril administered to healthy adult volunteers using orodispersible minitablets for use in pediatrics.
Faisal M; Cawello W; Burckhardt BB; Laer S
Drug Des Devel Ther; 2019; 13():481-490. PubMed ID: 30774312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
